LLY Jan 2025 850.000 call
| Previous Close | 94.80 |
| Open | 86.35 |
| Bid | 88.80 |
| Ask | 91.25 |
| Strike | 850.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 86.35 - 94.80 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 204 |
- Yahoo Finance Video
Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand. In contrast, shares of competitor Hims & Hers Health (HIMS) are plummeting following this news. Catalysts co-hosts Seana Smith and Brad Smith delve into the implications of this FDA action, analyzing how this development is likely to boost Eli Lilly's operations. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Angel Smith
Barrons.comEli Lilly’s Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers.
Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized on the pinch, are tumbling.
Insider MonkeyHere’s Why Eli Lilly and Company (LLY) Surged in Q2
PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund modestly underperformed the S&P 1500 Health Care Index in the quarter which declined 1.1%. Security selection within pharmaceuticals, MedTech, and health care provides & services contributed the most value during the quarter, […]
